Avascular Necrosis Market Research Report Information By Type (Trauma Related Avascular Necrosis (AVN) and Non-Trauma Related Avascular Necrosis (AVN)0, By Treatment (Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Cholesterol Lowing Drugs, Osteoporosis Drugs, Blood Thinners, and Others), By Diagnosis (Imaging, Biopsy, CT Scan, PET and X- Ray), By End User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Avascular Necrosis Market Overview

Avascular Necrosis Market Size was valued at USD 0.53 Billion in 2023. The Avascular Necrosis market industry is projected to grow from USD 0.564 Billion in 2024 to USD 0.881 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.72% during the forecast period (2024 - 2032). 

The rise in the percentage of individuals with incomes, the number of business experts, and the enormous increase in  population are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

March 2023: The U.S. Food and Drug Administration granted 510(k) approval to a total shoulder arthroplasty system featuring an ellipsoid anatomic head and a wholly convertible stem. In the FDA summary paper, indications for the use of the shoulder system in anatomic or reverse arthroplasty are detailed. Should a complete shoulder conversion in the opposite direction be required, it is possible to maintain the humeral stem while exchanging the articulating surfaces. 

Reconstruction of functional deformities, osteoarthritis (OA), avascular necrosis (AVN), and rheumatoid arthritis (RA) are all encompassed. With 510(k) certification, the device must be "substantially equivalent" to a "predicate" device. This product is virtually identical to the AltiVateTM Shoulder System with regard to intended use and indications, materials, size ranges, and design intent.

The US Food and Medicine Administration approved a phase II study of Regrow Biosciences' flagship product OSSGROW, an orphan medicine that aids in the efficient treatment of osteonecrosis, in May 2022, the company reported. Its intended users are those afflicted with Avascular Necrosis, which is alternatively referred to as Osteonecrosis. The accomplishment in question has reportedly propelled Regrow Biosciences closer to its goal of attaining a monopoly over the $5 billion global market, as stated in the organization's official statement. 

Osteonecrosis is a relatively uncommon condition in the West, whereas it is quite prevalent in Asia. OSSGROW ® has been granted Orphan Drug Designation (ODD) by the European Medicines Agency and the Food and Drug Administration of the United States. Following the conclusion of Phase 3 clinical trials in India, the organization revealed this information.

Avascular Necrosis Market Trends

• Growing accidents is driving the market growth

Market CAGR for avascular necrosis is being driven by the rising fatal accidents. Avascular necrosis is a condition that develops after a fractured hip or dislocation, a hard impact from an automobile accident, or both. As a result of car collisions in traffic accidents, people might suffer serious injuries such as fractured bones and dislocated hips, as well as blood flow difficulties. Traumatic injuries develop when the femoral head's dislocation and fracture cut off the blood supply to the area. 

Trauma injuries like fractures to the neck of the talus frequently occur as a result of car accidents, falls, sports injuries, natural disasters, and other physical mishaps that occur at home, at work, and while walking down the street. Avascular Necrosis is another condition commonly affecting kids and is brought on by cancer treatment. 

Avascular Necrosis of the proximal femoral head is known as Legg-Calvé-Perthes disease (LCPD), and it frequently affects kids between the ages of 4 and 10 years old. As a result, the demand for avascular necrosis market is fueled by the rise in traffic accidents, severe injuries, and occurrence in youngsters.

The bone marrow aspirate and concentration is a novel, practical method that detects hip avascular necrosis in its early stages. The surgeon removes a sample of the dead hipbone while operating on the bone marrow and replaces it with stem cells obtained from the bone marrow. Thus, bone marrow aspirate and concentration surgery are the most common technology for treating avascular Necrosis. Bone cell treatment, which treats avascular Necrosis (AVN) by employing the patient's cells as a therapeutic instrument, is the only long-term cure for the condition. 

The disease's progression is stopped by bone cell treatment, improving mobility. Another regenerative medicine technique is tissue engineering, which aids in regenerating the necrotic bone tissues and the vasculature in the femoral head, a key contributor to the condition. One of the key factors propelling the avascular necrosis market's revenue growth is the rise in avascular necrosis prevalence caused by an increase in unhealthy behaviors like alcohol or cigarette intake or smoking in a growing population.Avascular necrosis risk is increased by several chronic conditions, including diabetes, HIV, or by some unfavorable reactions to cancer therapy and organ transplants, which helps drive the avascular necrosis market's revenue growth. 

The market for avascular Necrosis is expanding due to the excessive use of steroids in numerous other treatments, which raises the risk of avascular Necrosis. Thus, driving the Avascular Necrosis market revenue.

Avascular Necrosis Market Segment Insights

Avascular Necrosis Type Insights

Based on type, the  Avascular Necrosis market segmentation includes trauma-related avascular necrosis (AVN) and non-trauma-related avascular necrosis (AVN). The non-trauma-related avascular necrosis (AVN) segment dominated the market, accounting for 66% of market revenue. The causes of these increases are increased alcohol consumption, metabolic bone disorders, and other illnesses. 

The main disability in young people is non-traumatic avascular necrosis of the femoral head, which has a high medical cost. The prevalence of femoral head necrosis has significantly grown in recent years due to rising testosterone usage and alcohol consumption.

Avascular Necrosis Treatment Insights

Based on Treatment, the  Avascular Necrosis market segmentation includes trauma-related nonsteroidal anti-inflammatory drugs (NSAIDs), cholesterol lowing drugs, osteoporosis drugs, blood thinners, and others. The cholesterol lowing drugs segment dominated the market. This increase is related to the possibility that reducing blood fat and cholesterol levels could prevent arterial blockages that cause avascular necrosis.

Avascular Necrosis Diagnosis Insights

Based on diagnosis, the  Avascular Necrosis market segmentation includes imaging, biopsy, CT Scan, PET and X-Ray. The CT scan segment dominated the market. The more accurate test for avascular necrosis diagnosis is CT scan, which is substantially more accurate than simple film radiography in detecting AVN. An in-depth view of the bone is provided by the CT scan, which produces 3D images of the bone. Compared to other diagnostic procedures, it provides a more accurate and conclusive diagnosis of a bone problem. The most common and effective procedure is hence MRI and CT scanning.

Avascular Necrosis End User Insights

Based on end users, the  Avascular Necrosis market segmentation includes hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment generated the most income (54%). The segment growth is fueled by the rising need for minimally invasive care and reliance on surgery to address osteonecrosis. Additionally, the market is being driven ahead by regional governments' improvements to the healthcare infrastructure and an increase in hospitalization options. 

Figure 1  Avascular Necrosis Market, by End User, 2023 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Avascular Necrosis Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Avascular Necrosis market area will dominate this market because it places a greater emphasis on the relevance of avascular necrosis in persons and accepts cutting-edge therapeutic techniques with greater frequency. The public's focus on avascular necrosis medical conditions and diagnostics in this area and the expanding senior population will likely drive the market's growth.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  AVASCULAR NECROSIS MARKET SHARE BY REGION 2023 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Avascular Necrosis market accounts for the second-largest market share, the large population's presence, and the rising number of people with Avascular Necrosis. Further, the German Avascular Necrosis market held the largest market share, and the UK Avascular Necrosis market was the fastest-growing market in the European region.

Between 2023 and 2032, the Asia-Pacific Avascular Necrosis Market is anticipated to see the fastest CAGR growth. Increasing the number of people with avascular necrosis, government initiatives to enhance public awareness, and a rise in demand for the therapy fuel the market's revenue growth. In addition, the Indian Avascular Necrosis market had the quickest growth rate in the Asia-Pacific region, while China's Avascular Necrosis market had the highest market share.

Avascular Necrosis Key Market Players & Competitive Insights

Leading industry companies are making significant R&D investments to diversify their product offerings, which will drive the Avascular Necrosis market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants also engage in several strategic actions to increase their worldwide presence. The Avascular Necrosis industry must provide affordable products to grow and thrive in a more competitive and challenging market environment.

Local manufacturing to cut operating costs is one of the key business tactics manufacturers use in the  Avascular Necrosis industry to help clients and expand the market sector In recent years, the Avascular Necrosis industry has offered some of the most significant advantages to medicine. Major players in the Avascular Necrosis market, including Dr. Reddy’s Laboratories Ltd., and others, are attempting to increase market demand by investing in research and development operations.

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical firm dedicated to offering cost-effective and cutting-edge medications for better lifestyles. Dr. Reddy offers a variety of goods and services, such as APIs, specialized pharmaceutical services, generics, biosimilars, and differentiated formulations, through its three companies, Pharmaceutical Services & Active Ingredients,  Generics, and Proprietary Products. Our primary therapeutic areas of interest are dermatology, cancer, diabetology, gastroenterology, and diabetology. Dr. Reddy has markets all over the world. The principal markets include the United States, India, the CIS nations, and Europe. 

In August 2021 As permitted by the U.S. Food and Drug Administration (USFDA), Dr. Reddy's Laboratories Ltd. declared the re-launch of OTC (over-the-counter) Naproxen Sodium Pills USP, 220 mg, the store-brand comparable of Aleve®, in the U.S. market.

Swiss and Americans founded Novartis AG. Novartis was the fourth largest by sales in 2022 and has consistently been rated in the top five ly. The Novartis Group is run by Novartis AG, a publicly traded Swiss holding corporation. Novartis AG directly or indirectly owns all businesses that function as subsidiaries of the Novartis Group ly. Three operating divisions make up Novartis's businesses Sandoz (generics), Innovative Medicines, and Alcon (eyecare).

In October 2020, Leqvio (inclisiran) has been approved by the European Commission (EC) for treating people with hypercholesterolemia or mixed dyslipidemia, according to a statement from Novartis. This approval is based on the strong ORION clinical development program's findings, which showed that Leqvio reduced low-density lipoprotein cholesterol (LDL-C) in individuals with increased LDL-C by up to 52% while still maximally tolerated by statin therapy. Leqvio is anticipated to support long-term adherence with two doses per year, after an initial dose and one at three months 1-3.

Key Companies in the Avascular Necrosis market include

• Novartis AG


• Pfizer Inc


• Teva Pharmaceutical Industries Ltd


• Mylan N.V


• Zimmer Biomet


• Merck & Co. Inc


• Enzo Biochem Inc


• Atnahs


• Bone Therapeutics SA


• Vericel Corporation.

Avascular Necrosis Market Segmentation

Avascular Necrosis Type Outlook

• Trauma Related Avascular Necrosis (AVN)


• Non-Trauma Related Avascular Necrosis (AVN)

Avascular Necrosis Treatment Outlook

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)


• Cholesterol Lowing Drugs


• Osteoporosis Drugs


• Blood Thinners


• Others

Avascular Necrosis Diagnosis Outlook

• Imaging


• Biopsy


• CT Scan


• PET


• X- Ray

Avascular Necrosis End user Outlook

• Hospital Pharmacies


• Retail Pharmacies


• Online Pharmacies

Avascular Necrosis Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America